In a groundbreaking step toward canine longevity, California-based biotech firm Loyal has achieved partial approval from the U.S. Food and Drug Administration (FDA) for its lifespan-extending drug, LOY-001. Veuer’s Maria Mercedes Galuppo has the story.
Category
🗞
NewsTranscript
00:00In a groundbreaking step toward canine longevity, California-based biotech firm Loyal has achieved
00:07partial approval from the U.S. Food and Drug Administration for its lifespan-extending
00:12drug Loy-1.
00:13The FDA's Center for Veterinary Medicine granted reasonable expectation of effectiveness approval
00:20for Loy-1, aimed at extending the lives of larger canine companions while maintaining
00:25their quality of life.
00:27The long-acting injectable drug, administered every three to six months by veterinarians,
00:32awaits final approval for manufacturing and safety.
00:36Loyal anticipates availability by 2026, reports Newsweek.
00:41Loy-1 targets age-associated diseases by addressing aging mechanisms, potentially preventing or
00:48delaying illness onset.
00:50However, skeptics urge more testing, expressing concerns about potential animal suffering.